Probi

Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.

Probi’s mission is to improve human health and wellbeing through innovative, science-based probiotics.

Probi strives to be the global leader in developing, manufacturing and supplying probiotics that contribute to human health and wellbeing.

Probi has been recognised globally for its commitment and achievements in the probiotics field. The company has been awarded the Edison Award for Medical & Health , the Gold Award for Health and Wellness , and the EU Research & Innovation Prize .